解释记忆门诊无痴呆患者阿尔茨海默病体液生物标志物浓度的变异性
MEMENTO队列纳入26家法国记忆门诊的2323例认知主诉或轻度认知障碍患者,分析AD临床特征及非AD相关因素对体液生物标志物浓度变异的解释比例。血液生物标志物变异主要由年龄、常规生物学检测、炎症标志物和样本前处理解释,而脑脊液变异主要由认知功能解释。作者认为血液生物标志物不宜作为独立的AD生物标志物。
要点
- 血液NfL、p181-tau、Aβ-42/40和total-tau浓度变异由AD临床特征解释的比例分别为13.7%、11.4%、3.0%和1.4%。
- 脑脊液NfL、Aβ-42/40、total-tau和p181-tau浓度变异由AD临床特征解释的比例分别为24.8%、22.3%、19.8%和17.2%。
- 控制变异驱动因素后,血液生物标志物预测A+和T+状态的性能保持不变。
核心结论
- AD血液生物标志物浓度的变异主要由年龄解释,认知、脑萎缩和遗传贡献较小,与脑脊液指标相反。
- 作者认为这些结果挑战了将血液生物标志物作为独立的AD生物标志物使用。
研究设计与样本
- MEMENTO队列纳入26家法国记忆门诊的2323例认知主诉或轻度认知障碍个体。
- 基线评估包括临床和神经心理学评估、脑MRI、淀粉样蛋白PET、脑脊液(可选)和血液采样。
- 血液生物标志物水平使用Simoa-HDX分析仪测定。
- 采用线性回归分析AD临床特征(认知、AD遗传风险评分和脑萎缩)建模生物标志物浓度,并纳入非AD相关协变量。
主要发现
- 共2257例参与者纳入分析,中位年龄71.7岁,女性占61.8%,高教育水平者占55.2%。
- 血液生物标志物中,AD临床特征解释的变异比例:NfL为13.7%,p181-tau为11.4%,Aβ-42/40为3.0%,total-tau为1.4%。
- 在纳入非AD相关因素的最终模型中,血液生物标志物变异主要由年龄、常规生物学检测、炎症标志物和样本前处理解释。
- 脑脊液中,AD临床特征解释的变异比例:NfL为24.8%,Aβ-42/40为22.3%,total-tau为19.8%,p181-tau为17.2%。
- 与血液生物标志物相反,脑脊液生物标志物在调整协变量后最大比例的变异由认知解释。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Patients' comorbidities can affect Alzheimer disease (AD) blood biomarker concentrations. Because a limited number of factors have been explored to date, our aim was to assess the proportion of the variance in fluid biomarker levels explained by the clinical features of AD and by a large number of non-AD-related factors. METHODS: MEMENTO enrolled 2,323 individuals with cognitive complaints or mild cognitive impairment in 26 French memory clinics. Baseline evaluation included clinical and neuropsychological assessments, brain MRI, amyloid-PET, CSF (optional), and blood sampling. Blood biomarker levels were determined using the Simoa-HDX analyzer. We performed linear regression analysis of the clinical features of AD (cognition, AD genetic risk score, and brain atrophy) to model biomarker concentrations. Next, we added covariates among routine biological tests, inflammatory markers, demographic and behavioral determinants, treatments, comorbidities, and preanalytical sample handling in final models using both stepwise selection processes and least absolute shrinkage and selection operator (LASSO). RESULTS: In total, 2,257 participants were included in the analysis (median age 71.7, 61.8% women, 55.2% with high educational levels). For blood biomarkers, the proportion of variance explained by clinical features of AD was 13.7% for neurofilaments (NfL), 11.4% for p181-tau, 3.0% for Aβ-42/40, and 1.4% for total-tau. In final models accounting for non-AD-related factors, the variance was mainly explained by age, routine biological tests, inflammatory markers, and preanalytical sample handling. In CSF, the proportion of variance explained by clinical features of AD was 24.8% for NfL, 22.3% for Aβ-42/40, 19.8% for total-tau, and 17.2% for p181-tau. In contrast to blood biomarkers, the largest proportion of variance was explained by cognition after adjustment for covariates. The covariates that explained the largest proportion of variance were also the most frequently selected with LASSO. The performance of blood biomarkers for predicting A+ and T+ status (PET or CSF) remained unchanged after controlling for drivers of variance. DISCUSSION: This comprehensive analysis demonstrated that the variance in AD blood biomarker concentrations was mainly explained by age, with minor contributions from cognition, brain atrophy, and genetics, conversely to CSF measures. These results challenge the use of blood biomarkers as isolated stand-alone biomarkers for AD.
引用
- Bouteloup V, Pellegrin I, Dubois B, et al. Explaining the Variability of Alzheimer Disease Fluid Biomarker Concentrations in Memory Clinic Patients Without Dementia. Neurology. 2024. PMID: 38527237. doi:10.1212/WNL.0000000000209219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。